Patel SA, Ng M, Nardello SM, Ruth K, Bleicher RJ. Immediate breast reconstruction for women having inflammatory breast cancer in the United States. Cancer Med. 2018;7:2887--2902. 10.1002/cam4.1546

Patel and Ng shared co‐first authorship.

This work was presented at the 2017 Society of Surgical Oncology 70th Annual Cancer Symposium, Seattle, Washington, March 16, 2017.

1. INTRODUCTION {#cam41546-sec-0001}
===============

Inflammatory breast cancer (IBC) is an uncommon and locally advanced cancer accounting for 0.5%‐2% of all newly diagnosed breast cancers in the United States.[1](#cam41546-bib-0001){ref-type="ref"}, [2](#cam41546-bib-0002){ref-type="ref"}, [3](#cam41546-bib-0003){ref-type="ref"}, [4](#cam41546-bib-0004){ref-type="ref"} Due to malignant infiltration of dermal lymphatics, IBC is typically aggressive, having a poor prognosis and overall survival.[2](#cam41546-bib-0002){ref-type="ref"} Survival is improved with multimodality therapy that consists of neoadjuvant chemotherapy and postmastectomy radiation therapy.[5](#cam41546-bib-0005){ref-type="ref"}, [6](#cam41546-bib-0006){ref-type="ref"}, [7](#cam41546-bib-0007){ref-type="ref"}, [8](#cam41546-bib-0008){ref-type="ref"} Most patients without systemic malignancy undergo modified radical mastectomy resulting in increased locoregional control.[3](#cam41546-bib-0003){ref-type="ref"}, [8](#cam41546-bib-0008){ref-type="ref"}

Traditionally, IBC was considered a relative contraindication for breast reconstruction due to concerns for margin positivity, high risk of recurrence, poor long‐term survival, and concern about potential delay of treatments from surgical complications.[9](#cam41546-bib-0009){ref-type="ref"}, [10](#cam41546-bib-0010){ref-type="ref"} The NCCN Breast Cancer Panel recommends delayed breast reconstruction as an option to women with IBC who have undergone a modified radical mastectomy.[9](#cam41546-bib-0009){ref-type="ref"} However, the surgical paradigm has not been re‐examined as IBC survival outcomes have improved with multimodality treatment. If IBC patients can safely undergo breast reconstruction, they may benefit because of its ability to enhance body image, self‐esteem, and quality of life.[11](#cam41546-bib-0011){ref-type="ref"}, [12](#cam41546-bib-0012){ref-type="ref"}

Reduction in delays to surgical treatment of breast cancer has the potential to improve overall and disease‐specific survival, comparable to the addition of some standard therapy.[13](#cam41546-bib-0013){ref-type="ref"} A recent review determined that immediate breast reconstruction (IBR) did not delay initiation of adjuvant chemotherapy.[14](#cam41546-bib-0014){ref-type="ref"}, [15](#cam41546-bib-0015){ref-type="ref"} Small, single‐institution studies have suggested that performing delayed or immediate autologous reconstruction in the setting of IBC is safe and does not impact disease‐free and overall survival,[16](#cam41546-bib-0016){ref-type="ref"}, [17](#cam41546-bib-0017){ref-type="ref"} but because of its low incidence and poor survival, there is a paucity of literature evaluating the relationship of IBR to survival.

While prior reports have noted that chronologic age[18](#cam41546-bib-0018){ref-type="ref"}, [19](#cam41546-bib-0019){ref-type="ref"} and comorbidities[20](#cam41546-bib-0020){ref-type="ref"} thought to preclude breast reconstruction were some of the reasons for the infrequent rate of mastectomy with IBR, recent studies have demonstrated an increase in the use of postmastectomy IBR for breast cancer patients.[21](#cam41546-bib-0021){ref-type="ref"}, [22](#cam41546-bib-0022){ref-type="ref"} Moreover, a recent analysis of the National Cancer Database found that mastectomy and IBR rates are increasing among all patients age 65 years and older. The life expectancy of a women aged 65 years is age 86 years.[23](#cam41546-bib-0023){ref-type="ref"} Anecdotally we have had patients increasingly request IBR in the IBC setting. This study evaluated survival after treatment of IBC with and without IBR in the ≥65 year old population using one of the largest United States datasets: the Surveillance, Epidemiology, and End Results (SEER)‐Medicare‐linked database, to inform clinical decision‐making and patient counseling, and re‐evaluate management guidelines.

2. METHODS {#cam41546-sec-0002}
==========

The Fox Chase Cancer Center institutional review board approved the study, and permission to use the SEER‐Medicare database was obtained from the National Cancer Institute (NCI). All sixteen applicable SEER registries were used to increase the external generalizability of the results.

The SEER cancer diagnosis date is specified by only month and year. Medicare claims were searched from the start of the month of diagnosis and for an additional 13 months. Patients were not excluded based on history of prior or other cancer, or on receipt of radiotherapy or chemotherapy. Patients were included if they had nonmetastatic IBC as indicated by AJCC 6th edition stage T4d ("Inflammatory carcinoma") for cases diagnosed 2004‐2009; or extent of disease code 70 ("Inflammatory carcinoma, including diffuse (beyond that directly overlying the tumor) dermal lymphatic permeation or infiltration") for IBC diagnosed 1991‐2003. The dates of diagnoses between 1991 until 2009 were chosen to include sufficient length of follow‐up (ie, 5 years). Additionally, the cohort included females diagnosed ≥65 years of age having complete staging and diagnosis date variables, who had Medicare claims for mastectomy to permit the identification of the breast and reconstruction surgery status and dates. Medicare claims codes for surgery were identified to evaluate the interval between mastectomy and reconstruction procedures (Table [S1](#cam41546-sup-0001){ref-type="supplementary-material"}). Surgery dates and receipt of chemotherapy and radiotherapy were derived from physician claims, supplemented by outpatient and inpatient hospital claims. All submitted Medicare claims were reviewed for relevant procedures and dates. Charlson Comorbidity Index (CCI) was estimated from Medicare claims diagnosis codes using a modified method of Klabunde.[24](#cam41546-bib-0024){ref-type="ref"}

Patient demographic, tumor, and treatment characteristics were considered potential confounders, including age at diagnosis, race (per Medicare), marital status, CCI, United States region, census tract poverty level, census tract median income, year of diagnosis, tumor grade, tumor receptor status, lymph node (LN) status, radiotherapy, and chemotherapy use. The association of each characteristic with immediate reconstruction was evaluated using logistic regression.

Two survival outcomes of IBC patients, breast cancer‐specific mortality (BCSM), and overall mortality (OM) were investigated using SEER vital status and cause of death. Competing risk regression mortality analysis was used to evaluate the association of IBR with BCSM while accounting for competing risk of death from other causes, and standardization of follow‐up dates based on date of treatment. Risk comparisons are reported as sub‐distribution hazard ratios (sub‐HR). Similarly, Cox proportional hazards regression was used to estimate hazard ratios \[HR\] for the OM outcome. Three levels of covariate adjustment were examined: (1) adjustment for age at diagnosis; (2) further adjustment for statistically significant characteristics (*P* \< .05) associated with immediate reconstruction; and (3) adjustment for all covariates in Table 3. Comparative cumulative incidence functions illustrate the sub‐HR difference between IBR and no reconstruction with all other covariates held constant. Statistical significance was set at *P *=* *.05 (two‐sided). Analyses were performed using SAS software, version 9.3 (SAS Institute) and Stata software, release 12 (StataCorp 2011).

3. RESULTS {#cam41546-sec-0003}
==========

3.1. Characteristics of inflammatory breast cancer cohort {#cam41546-sec-0004}
---------------------------------------------------------

Among patients in the SEER‐Medicare breast cancer dataset (1991‐2009), we identified 1472 IBC patients meeting inclusion criteria, and 44 IBC patients having complete claims for surgical intervention and treatment (Table [1](#cam41546-tbl-0001){ref-type="table"}). Mean age of diagnosis was 75.5 (range 65‐103) years old. The cohort was primarily Caucasian (83.9%), married (36.9%), and healthy with CCI ≤1 (58.5%). Most were living within a 5%‐10% poverty census tract (30%) and reported \$25 000‐\$50 000 median income. The number of women diagnosed with IBC increased nearly 1.5‐fold each period until 2001‐2004.

###### 

Distribution of patient and oncologic characteristics of inflammatory breast cancer patients from the SEER‐Medicare 1991‐2009 Database (n = 1472)

  Demographic characteristics                             n                         \%     Tumor characteristics          n      \%
  ------------------------------------------------------- ------------------------- ------ ------------------------------ ------ -------
  Age at diagnosis (y)                                    AJCC stage                                                             
  Age 65‐69                                               383                       26.0   Stage IIIB (3rd, 6th)          1304   88.6
  Age 70‐74                                               366                       24.9   Stage IIIC (6th)               119    8.1
  Age 75‐79                                               289                       19.6   NOS or unknown                 49     3.3
  Age 80‐84                                               234                       15.9   T‐stage                               
  Age \>85                                                200                       13.6   002‐025 mm                     123    8.4
  Race (Medicare)                                         026‐050 mm                225    15.3                                  
  White                                                   1235                      83.9   051‐270 mm                     301    20.4
  Black                                                   153                       10.4   Diffuse                        680    46.2
  Other                                                   84                        5.7    Unknown                        143    9.7
  Marital status                                          Grade                                                                  
  Not married                                             321                       21.8   Well‐differentiated            44     3.0
  Married                                                 543                       36.9   Moderately‐differentiated      354    24.0
  Widowed                                                 608                       41.3   Poorly or undifferentiated     867    58.9
  Charlson Comorbidity Index                              NOS                       207    14.1                                  
  0                                                       464                       31.5   Histology                             
  1                                                       397                       27.0   Inflammatory breast cancer     752    51.1
  2‐3                                                     406                       27.6   Ductal cancer                  529    35.9
  4‐11                                                    205                       13.9   Other                          191    13.0
  Region in U.S.[a](#cam41546-note-0030){ref-type="fn"}   Receptor status                                                        
  Northeast                                               241                       16.4   Any positive receptor          772    52.4
  South                                                   256                       17.4   Negative receptors (ER‐/PR‐)   457    31.0
  Midwest                                                 255                       17.3   Unknown                        243    16.5
  West                                                    720                       48.9   Lymph nodes examined                  
  Urban/Rural[b](#cam41546-note-0031){ref-type="fn"}      None                      298    20.2                                  
  Big Metro                                               750                       51.0   1‐11                           552    37.5
  Metro                                                   480                       32.6   \>12                           545    37.0
  Urban                                                   84                        5.7    Unknown                        77     5.2
  Less Urban/Rural                                        158                       10.7   Lymph nodes positive                  
                                                          No lymph nodes examined   298    20.2                                  
  0%‐5%                                                   397                       27.0   0                              146    9.9
  5%‐10%                                                  442                       30.0   1‐3                            274    18.6
  10%‐20%                                                 397                       27.0   4‐9                            355    24.1
  \>20%                                                   236                       16.0   \>10                           337    22.9
  Median income within census tract                       Unknown                   62     4.2                                   
  \<\$25 000                                              155                       10.5   Treatment Characteristics             
  \$25 000‐\$50 000                                       844                       57.3   Radiation therapy (XRT)               
  \$50 000‐\$75 000                                       348                       23.6   XRT                            893    60.7
  \>\$75 000                                              125                       8.5    No XRT                         579    39.3
  Year of diagnosis                                       Chemotherapy status                                                    
  1991‐1995                                               231                       15.7   Yes                            957    65.0
  1996‐2000                                               344                       23.4   No                             515    35.0
  2001‐2004                                               485                       32.9   Surgery                               
  2005‐2009                                               412                       28.0   Mastectomy                     1472   100.0

Region groupings are as follows: Northeast (Connecticut and New Jersey); South (Atlanta, rural Georgia, Kentucky, and Louisiana); Midwest (Detroit and Iowa); West (Hawaii, New Mexico, Seattle, Utah and California).

Urban/rural setting definitions are: Large metro=counties in Metro areas of \>/= 1,000,000 population; Metro=counties in metro areas of 250,000 to 1,000,000 population; Urban=urban population \>/= 20,000 adjacent or nonadjacent to a metro area; Less urban/rural or rural population of \<20,000.
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Most patients were Stage IIIB (88.6%) and had T4d presentation (46.2%). The most common tumor biology was poorly differentiated/undifferentiated grade (58.9%), IBC histology (51.1%), and any positive hormone receptor (HR) (52.4%). Nearly 75% had at least 1 lymph node (LN) examined and had at least 1 positive LN in 65.6% of patients. All IBC patients underwent mastectomy (n = 1472), and the majority received chemotherapy (65%) and radiation therapy (60.7%).

3.2. Demographic and tumor characteristics associated with immediate breast reconstruction {#cam41546-sec-0005}
------------------------------------------------------------------------------------------

Immediate breast reconstruction patients (3%, n = 44) were younger compared to their nonreconstructed counterparts (mean = 72.6 vs 75.6 years, *P* = .008) (Table [2](#cam41546-tbl-0002){ref-type="table"}). Immediate breast reconstruction was associated with marriage (*P* = .016), lower CCI (*P* = .029), and greater census tract median income (*P* = .024). Trend analyses demonstrated that fewer IBRs occurred with increasing age at diagnosis (*P* = .0050), CCI score (*P* = .0042), and census tract poverty (*P* = .0099). An inverted‐U trend of IBR was associated with increasing median income (*P* = .0033), where the greatest proportion of IBR was performed among patients reporting a median income of \$25 000‐\$75 000. Associations between IBR and characteristics of IBC patients are delineated in Table [S2](#cam41546-sup-0001){ref-type="supplementary-material"}. Notably, patients with poor health as denoted by a greater CCI score were significantly less likely to undergo IBR (CCI 1 vs 0, OR = 0.77; CCI 2‐3, OR = 0.32; CCI 4‐11, OR = 0.31; *P* = .041). When adjusted for marital status, CCI, and median income on multivariable analyses, the only independent predictor of undergoing IBR was median income (*P* = .047). Analysis of the ICD‐9 implant‐related complications in our cohort was a 7% (n = 3, *P* \< .003) rate of mechanical complication due to breast implant in the IBC group undergoing breast reconstruction (n = 44), compared to the no‐reconstruction groups (0%, n = 1428).

###### 

Association of immediate reconstruction with patient and oncologic characteristics in inflammatory breast cancer patients (n = 1472)

                                                          No immediate reconstruction (n = 1428)   Immediate reconstruction (n = 44)   *P* [c](#cam41546-note-0006){ref-type="fn"}          
  ------------------------------------------------------- ---------------------------------------- ----------------------------------- --------------------------------------------- ------ ---------------------------------------------
  **Patient characteristics**                                                                                                                                                               
  Age at diagnosis, mean (SD)                             75.6 (7.6)                                                                   72.6 (6.1)                                           .008[d](#cam41546-note-0007){ref-type="fn"}
  Age group at diagnosis                                                                                                                                                                    
  Ages 65‐69                                              366                                      25.6                                17                                            38.6   .091
  Ages 70‐74                                              352                                      24.6                                14                                            31.8   
  Ages 75‐79                                              282                                      19.7                                [a](#cam41546-note-0003){ref-type="fn"}              
  Ages 80‐84                                              230                                      16.1                                [a](#cam41546-note-0003){ref-type="fn"}              
  Ages \>85                                               198                                      13.9                                [a](#cam41546-note-0003){ref-type="fn"}              
  Race                                                                                                                                                                                      
  White                                                   1196                                     83.8                                39                                            88.6   .769
  Black                                                   149                                      10.4                                [a](#cam41546-note-0003){ref-type="fn"}              
  Other                                                   83                                       5.8                                 [a](#cam41546-note-0003){ref-type="fn"}              
  Marital status                                                                                                                                                                            
  Married                                                 520                                      36.4                                23                                            52.3   .016
  Not married                                             309                                      21.6                                [a](#cam41546-note-0003){ref-type="fn"}              
  Widowed                                                 599                                      41.9                                [a](#cam41546-note-0003){ref-type="fn"}              
  Charlson Comorbidity Index                                                                                                                                                                
  0                                                       443                                      31.0                                21                                            47.7   .029
  1                                                       383                                      26.8                                14                                            31.8   
  2‐3                                                     400                                      28.0                                [a](#cam41546-note-0003){ref-type="fn"}              
  4‐11                                                    202                                      14.1                                [a](#cam41546-note-0003){ref-type="fn"}              
  Region in U.S.[b](#cam41546-note-0004){ref-type="fn"}                                                                                                                                     
  Northeast                                               233                                      16.3                                [a](#cam41546-note-0003){ref-type="fn"}              .188
  South                                                   250                                      17.5                                [a](#cam41546-note-0003){ref-type="fn"}              
  Midwest                                                 252                                      17.6                                [a](#cam41546-note-0003){ref-type="fn"}              
  West                                                    693                                      48.5                                27                                            61.4   
  Urban/Rural[c](#cam41546-note-0006){ref-type="fn"}                                                                                                                                        
  Large Metro                                             724                                      50.7                                26                                            59.1   .778
  Metro                                                   467                                      32.7                                13                                            29.5   
  Urban                                                   82                                       5.7                                 [a](#cam41546-note-0003){ref-type="fn"}              
  Less Urban/Rural                                        155                                      10.9                                [a](#cam41546-note-0003){ref-type="fn"}              
                                                                                                                                                                                            
  0%‐5%                                                   378                                      26.5                                19                                            43.2   .064
  5%‐10%                                                  431                                      30.2                                11                                            25.0   
  10%‐20%                                                 386                                      27.0                                [a](#cam41546-note-0003){ref-type="fn"}              
  \>20%                                                   233                                      16.3                                [a](#cam41546-note-0003){ref-type="fn"}              
  Median Income within Census tract                                                                                                                                                         
  \<\$25 000                                              152                                      10.6                                [a](#cam41546-note-0003){ref-type="fn"}              .024
  \$25 000‐\$50 000                                       825                                      57.8                                19                                            43.2   
  \$50 000‐\$75 000                                       335                                      23.5                                13                                            29.5   
  \>\$75 000                                              116                                      8.1                                 [a](#cam41546-note-0003){ref-type="fn"}              
  Year of Dx                                                                                                                                                                                
  1991‐1995                                               223                                      15.6                                [a](#cam41546-note-0003){ref-type="fn"}              .786
  1996‐2000                                               332                                      23.2                                [a](#cam41546-note-0003){ref-type="fn"}              
  2001‐2004                                               473                                      33.1                                12                                            27.3   
  2005‐2009                                               400                                      28.0                                12                                            27.3   
  **Oncologic characteristics**                                                                                                                                                             
  AJCC stage                                                                                                                                                                                
  Stage IIIB (3rd, 6th)                                   1268                                     88.8                                36                                            81.8   .171
  Stage IIIC (6th)                                        114                                      8.0                                 [a](#cam41546-note-0003){ref-type="fn"}              
  NOS or unknown                                          46                                       3.2                                 [a](#cam41546-note-0003){ref-type="fn"}              
  T‐stage                                                                                                                                                                                   
  002‐025 mm                                              122                                      8.5                                 [a](#cam41546-note-0003){ref-type="fn"}              .542
  026‐050 mm                                              218                                      15.3                                [a](#cam41546-note-0003){ref-type="fn"}              
  051‐270 mm                                              292                                      20.4                                [a](#cam41546-note-0003){ref-type="fn"}              
  Diffuse                                                 656                                      45.9                                24                                            54.5   
  Unknown                                                 140                                      9.8                                 [a](#cam41546-note-0003){ref-type="fn"}              
  Grade                                                                                                                                                                                     
  Well‐differentiated                                     42                                       2.9                                 [a](#cam41546-note-0003){ref-type="fn"}              .734
  Moderately‐differentiated                               341                                      23.9                                13                                            29.5   
  Poorly or undifferentiated                              844                                      59.1                                23                                            52.3   
  NOS                                                     201                                      14.1                                [a](#cam41546-note-0003){ref-type="fn"}              
  Histology                                                                                                                                                                                 
  Inflammatory breast cancer                              731                                      51.2                                21                                            47.7   .580
  Ductal cancer                                           514                                      36.0                                [a](#cam41546-note-0003){ref-type="fn"}              
  Other                                                   183                                      12.8                                [a](#cam41546-note-0003){ref-type="fn"}              
  Receptor status                                                                                                                                                                           
  Any positive receptor                                   748                                      52.4                                24                                            54.5   .872
  Negative receptors (ER‐/PR‐)                            443                                      31.0                                [a](#cam41546-note-0003){ref-type="fn"}              
  Unknown                                                 237                                      16.6                                [a](#cam41546-note-0003){ref-type="fn"}              
  Lymph nodes examined                                                                                                                                                                      
  None                                                    288                                      20.2                                [a](#cam41546-note-0003){ref-type="fn"}              .815
  1‐11                                                    536                                      37.5                                16                                            36.4   
  \>12                                                    528                                      37.0                                17                                            38.6   
  Unknown                                                 76                                       5.3                                 [a](#cam41546-note-0003){ref-type="fn"}              
  Lymph nodes positive                                                                                                                                                                      
  No lymph nodes examined                                 288                                      20.2                                [a](#cam41546-note-0003){ref-type="fn"}              .887
  0                                                       141                                      9.9                                 [a](#cam41546-note-0003){ref-type="fn"}              
  1‐3                                                     264                                      18.5                                [a](#cam41546-note-0003){ref-type="fn"}              
  4‐9                                                     347                                      24.3                                [a](#cam41546-note-0003){ref-type="fn"}              
  \>10                                                    327                                      22.9                                [a](#cam41546-note-0003){ref-type="fn"}              
  Unknown                                                 61                                       4.3                                 [a](#cam41546-note-0003){ref-type="fn"}              
  Radiation therapy (XRT)                                                                                                                                                                   
  XRT                                                     861                                      60.3                                32                                            72.7   .096
  No XRT                                                  567                                      39.7                                12                                            27.3   
  Chemotherapy status                                                                                                                                                                       
  Yes                                                     927                                      64.9                                30                                            68.2   .655
  No                                                      501                                      35.1                                14                                            31.8   

As per National Cancer Institute Surveillance, Epidemiology, and End Results‐Medicare requirements, cells containing \<11 individuals and any cells making them calculable have been censored.

Region groupings are as follows: Northeast (Connecticut and New Jersey); South (Atlanta, rural Georgia, Kentucky, and Louisiana); Midwest (Detroit and Iowa); West (Hawaii, New Mexico, Seattle, Utah and California).

*P*‐value for difference in characteristic by reconstruction status using Chi‐square test or Fischer's exact test.

*P*‐value for age as a continuous variable using *t*‐test.
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3.3. Breast cancer‐specific and overall mortality {#cam41546-sec-0006}
-------------------------------------------------

In univariate analysis (Table [3](#cam41546-tbl-0003){ref-type="table"}), IBR was not associated with greater BCSM (sHR = 1.04, CI 0.71‐1.54; *P* = .83). Factors associated with greater BCSM included earlier year of IBC diagnosis (*P* = .0016), histologic grade other than well‐differentiated (*P* \< .0001), ER‐negative/PR‐negative or unknown receptor status (sHR = 2.02 and 1.47, respectively, *P* \< .0001), increasing number of positive LN (*P* \< .0001), and either neoadjuvant or adjuvant chemotherapy (*P* = .0027). Having 1‐11 or \>12 LN examined was associated with lower BCSM. Breast cancer‐specific mortality was not associated with age of diagnosis, race, marital status, U.S. region, socioeconomic factors, CCI, and radiation therapy.

###### 

Univariable and multivariable models of breast cancer‐specific mortality (BCSM) in inflammatory breast cancer patients undergoing immediate reconstruction (n = 1472)

                                                          Total (n = 1472)   BCSM (n = 710)                            UVA    MVA                                                    
  ------------------------------------------------------- ------------------ ----------------------------------------- ------ ---------------- ------------- ------ ---------------- -------------
  Immediate reconstruction                                                                                                                                                           
  Yes                                                     44                 23                                        1.04   \[0.71, 1.54\]   **.8295**     1.14   \[0.71, 1.76\]   **.5472**
  No                                                      1428               687                                       1.00   ---              1.00          ---                     
  ***Patient characteristics***                                                                                                                                                      
  Age at diagnosis                                                                                                     1.10   \[0.99, 1.01\]   .8406         1.01   \[1.00, 1.02\]   **.0992**
  Race (Medicare)                                                                                                                              **.9337**                             
  White                                                   1235               597                                       1.00   ---                                                    
  Black                                                   153                76                                        1.04   \[0.81, 1.33\]   .737                                  
  Other                                                   84                 37                                        0.98   \[0.70, 1.37\]   .8965                                 
  Marital status                                                                                                                               **.5991**                             
  Not married                                             273                140                                       1.00   ---                                                    
  Married                                                 543                251                                       0.87   \[0.71, 1.06\]   .1718                                 
  Widowed                                                 608                296                                       0.91   \[0.75, 1.11\]   .3482                                 
  Unknown                                                 48                 23                                        0.92   \[0.60, 1.41\]   .7077                                 
  Charlson Comorbidity Index                                                                                                                   **.7118**                             
  0                                                       464                237                                       1.00   ---                                                    
  1                                                       397                186                                       0.99   \[0.82, 1.19\]   .9123                                 
  2‐3                                                     406                189                                       1.00   \[0.83, 1.20\]   .9714                                 
  4‐11                                                    205                98                                        1.14   \[0.89, 1.45\]   .2921                                 
  Region of U.S.[b](#cam41546-note-0011){ref-type="fn"}                                                                                        **.1601**                             
  Northeast                                               241                123                                       1.00   ---                                                    
  South                                                   256                119                                       0.93   \[0.73, 1.20\]   .5797                                 
  Midwest                                                 255                142                                       1.01   \[0.80, 1.28\]   .9122                                 
  West                                                    720                326                                       0.84   \[0.68, 1.03\]   .0921                                 
  Census Tract Poverty                                                                                                                         **.8439**                             
  0%‐5%                                                   397                187                                       1.00   ---                                                    
  5%‐10%                                                  442                213                                       1.07   \[0.88, 1.30\]   .5113                                 
  10%‐20%                                                 397                194                                       1.08   \[0.89, 1.31\]   .4468                                 
  \>20%                                                   236                116                                       1.09   \[0.87, 1.38\]   .4523                                 
  Median Income                                                                                                                                **.563**                              
  \<\$25 000                                              155                84                                        1.13   \[0.89, 1.42\]   .3218                                 
  \$25 000‐\$50 000                                       844                406                                       1.00   ---                                                    
  \$50 000‐\$75 000                                       348                165                                       1.02   \[0.85, 1.22\]   .8276                                 
  \>\$75 000                                              125                55                                        0.88   \[0.67, 1.17\]   .3849                                 
  Year of diagnosis                                                                                                                            **.0016**                             **.0003**
  1991‐1994                                               172                110                                       1.00   ---                            1.00   ---              
  1995‐1997                                               177                15                                        0.93   \[0.72, 1.21\]   .6037         0.80   \[0.61, 1.05\]   
  1998‐2000                                               226                137                                       0.93   \[0.73, 1.17\]   .5251         0.77   \[0.60, 0.99\]   
  2001‐2003                                               374                186                                       0.75   \[0.60, 0.94\]   .0142         0.68   \[0.53, 0.86\]   
  2004‐2006                                               337                130                                       0.67   \[0.52, 0.85\]   .0013         0.57   \[0.44, 0.74\]   
  2007‐2009                                               186                42                                        0.61   \[0.43, 0.87\]   .0065         0.53   \[0.37, 0.75\]   
  ***Oncologic characteristics***                                                                                                                                                    
  Grade                                                                                                                                        **\<.0001**                           **.0005**
  Well‐differentiated                                     44                 [a](#cam41546-note-0010){ref-type="fn"}   1.00   ---                            1.00   ---              
  Moderately‐differentiated                               354                144                                       2.45   \[1.30, 4.60\]   .0055         2.72   \[1.45, 5.13\]   
  Poorly or undifferentiated                              867                464                                       3.68   \[1.98, 6.83\]   \<.0001       3.19   \[1.71, 5.95\]   
  NOS                                                     207                [a](#cam41546-note-0010){ref-type="fn"}   2.73   \[1.44, 5.19\]   .0021         2.51   \[1.32, 4.79\]   
  Receptor status                                                                                                                              **\<.0001**                           **\<.0001**
  Any positive receptor                                   772                310                                       1.00   ---                            1.00   ---              
  Negative receptors (ER‐/PR‐)                            457                269                                       2.02   \[1.71, 2.38\]   \<.0001       2.01   \[1.69, 2.39\]   
  Unknown                                                 243                131                                       1.47   \[1.20, 1.80\]   .0002         1.37   \[1.11, 1.69\]   
  Lymph nodes examined                                                                                                                         **.0022**                             **\<.0001**
  None                                                    298                165                                       1.00   ---                            1.00   ---              
  1‐11                                                    552                251                                       0.78   \[0.64, 0.95\]   .0128         0.43   \[0.30, 0.63\]   
  \>12                                                    545                247                                       0.79   \[0.65, 0.96\]   .018          0.32   \[0.21, 0.47\]   
  Unknown                                                 77                 47                                        1.27   \[0.91, 1.77\]   .1605         0.47   \[0.22, 1.03\]   
  Lymph nodes positive                                                                                                                         **\<.0001**                           **\<.0001**
  No lymph nodes examined                                 146                36                                        1.00   ---                            1.00   ---              
  0                                                       274                97                                        1.43   \[0.98, 2.09\]   .0675         1.64   \[1.11, 2.42\]   
  1‐3                                                     355                172                                       3.01   \[2.11, 4.29\]   \<.0001       4.05   \[2.76, 5.94\]   
  4‐9                                                     337                198                                       2.22   \[1.55, 3.18\]   \<.0001       2.54   \[1.76, 3.66\]   
  \>10                                                    62                 42                                        3.82   \[2.42, 6.04\]   \<.0001       3.51   \[1.55, 7.97\]   
  ***Treatment characteristics***                                                                                                                                                    
  Radiation therapy (XRT)                                                                                                                                                            
  XRT                                                     893                443                                       1.08   \[0.93, 1.26\]   **.3003**                             
  No XRT                                                  579                267                                       1.00   ---                                                    
  Pre‐Op XRT                                                                                                                                                                         
  Yes                                                     63                 34                                        1.09   \[0.77, 1.54\]   **.649**                              
  No                                                      1409               676                                       1.00   ---                                                    
  Post‐Op XRT                                                                                                                                                                        
  Yes                                                     839                414                                       1.07   \[0.92, 1.24\]   **.3722**                             
  No                                                      633                296                                       1.00   ---                                                    
  Chemotherapy status                                                                                                                                                                
  Yes                                                     957                489                                       1.28   \[1.09, 1.50\]   **.0027**                             
  No                                                      515                221                                       1      ---                                                    
  Pre‐Op chemotherapy                                                                                                                                                                
  Yes                                                     696                362                                       1.24   \[1.07, 1.43\]   **.0040**     1.36   \[1.14, 1.61\]   .0006
  No                                                      776                348                                       1.00   ---                            1.00   ---              
  Post‐Op Chemotherapy                                                                                                                                                               
  Yes                                                     723                373                                       1.19   \[1.03, 1.38\]   **.0206**     1.04   \[0.8, 1.23\]    .638
  No                                                      749                337                                       1.00   ---                            1.00   ---              

*P*‐value in bold denote Wald joint Chi‐square tests for overall significance of the predictor in the model.

*P*‐value not in bold are for pairwise comparisons with the referent.

As per National Cancer Institute Surveillance, Epidemiology, and End Results‐Medicare requirements, cells containing \<11 individuals and any cells making them calculable have been censored.

Region groupings are as follows: Northeast (Connecticut and New Jersey); South (Atlanta, rural Georgia, Kentucky, and Louisiana); Midwest (Detroit and Iowa); West (Hawaii, New Mexico, Seattle, Utah and California).
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In multivariate analysis (Table [3](#cam41546-tbl-0003){ref-type="table"}) including IBR and significant univariate factors, IBR was not associated with BCSM (sHR = 1.14, CI 0.71‐1.76; *P* = .55). Independent BCSM predictors were year of IBC diagnosis (*P* = .0003), histologic grade (*P* = .0005), HR status (*P* \< .0001), number of LN examined (*P* \< .0001), number of positive LN (*P* \< .0001), and neoadjuvant chemotherapy (*P* = .0006). Aggressive histologic grade and HR status were associated with increased risk of BCSM. Compared to well‐differentiated histologic grade, there is a threefold BCSM risk with poorly differentiated or undifferentiated grade IBC (sHR 3.19, CI 1.71‐5.95, *P* = .005), and a twofold increase of BCSM risk with ER‐negative/PR‐negative hormone status (sHR 2.01, CI 1.69‐2.39, *P* = .0005).

In univariate analysis (Table [4](#cam41546-tbl-0004){ref-type="table"}), IBR was associated with lower OM (HR = 0.63, CI 0.42‐0.92; *P* = .018). Factors associated with increased OM included older age at diagnosis (*P* \< .0001), single or widowed status (*P* = .0005), higher CCI (*P* \< .0001), poorer histologic grade (*P* = .0008), negative or unknown HR status (*P* \< .0001), unknown or no LN examined (*P* \< .0001), increased number of positive LN (*P* \< .0001), no neoadjuvant nor adjuvant radiation therapy (*P* \< .0001), no neoadjuvant chemotherapy (*P* \< .0010), and no adjuvant chemotherapy (*P* \< .0001). Overall mortality did not differ by race, U.S. region, census tract poverty, median income, and year of IBC diagnosis.

###### 

Univariable and multivariable models of overall mortality (OM) in inflammatory breast cancer patients undergoing immediate reconstruction (n = 1472)

                                                          n (n = 1472)   OM (n = 1056)   UVA    MVA                                                   
  ------------------------------------------------------- -------------- --------------- ------ ---------------- ------------ ------ ---------------- ------------
  Immediate reconstruction                                                                                                                            
  Yes                                                     44             26              0.63   \[0.42, 0.92\]   .018         0.82   \[0.55, 1.21\]   **.319**
  No                                                      1428           1030            1.00   ---                                                   
  **Patient characteristics**                                                                                                                         
  Age at diagnosis                                                                       1.04   \[1.03, 1.05\]   **\<.001**   1.03   \[1.02, 1.04\]   **\<.001**
  Race (Medicare)                                                                                                **.368**                             
  White                                                   1235           885             1.00   ---                                                   
  Black                                                   153            117             1.11   \[0.92, 1.35\]   .285                                 
  Other                                                   84             54              0.89   \[0.68, 1.17\]   .404                                 
  Marital status                                                                                                 **\<.001**                           **.861**
  Not married                                             273            192             1.00   ---                           ---                     
  Married                                                 543            359             0.84   \[0.70, 1.00\]   0.051        1.11   \[0.92, 0.77\]   
  Widowed                                                 608            472             1.13   \[0.95, 1.33\]   0.164        1.14   \[0.96, 0.81\]   
  Unknown                                                 48             33              0.94   \[0.65, 1.36\]   0.754        1.39   \[0.96, 0.66\]   
  Charlson Comorbidity Index                                                                                     **\<.001**                           **\<.001**
  0                                                       464            314             1.00   ---                                  1.00             ---
  1                                                       397            265             1.20   \[1.02, 1.42\]   .028         1.15   \[1.00, 1.39\]   
  2‐3                                                     406            315             1.68   \[1.44, 1.97\]   \<.001       1.50   \[1.29, 1.79\]   
  4‐11                                                    205            162             2.25   \[1.86, 2.73\]   \<.001       1.98   \[1.64, 2.43\]   
  Region of U.S.[a](#cam41546-note-0016){ref-type="fn"}                                                          **.057**                             
  Northeast                                               241            183             1.00   ---                                                   
  South                                                   256            166             0.85   \[0.69, 1.05\]   .135                                 
  Midwest                                                 255            197             0.79   \[0.64, 0.97\]   .021                                 
  West                                                    720            510             0.80   \[0.68, 0.95\]   .010                                 
  Census Tract Poverty                                                                                           **.366**                             
  0%‐5%                                                   397            284             1.00   ---                                                   
  5%‐10%                                                  442            312             1.04   \[0.87, 1.22\]                                        
  10%‐20%                                                 397            279             1.03   \[0.87, 1.22\]                                        
  \>20%                                                   236            181             1.18   \[0.98, 1.42\]                                        
  Median Income                                                                                                  **.287**                             
  \<\$25 000                                              155            131             1.15   \[0.95, 1.39\]   .160                                 
  \$25 000‐\$50 000                                       844            602             1.00   ---                                                   
  \$50 000‐\$75 000                                       348            242             1.01   \[0.87, 1.18\]   .857                                 
  \>\$75 000                                              125            81              0.88   \[0.69, 1.10\]   .261                                 
  Year of diagnosis                                                                                              **.396**                             
  1991‐1994                                               172            165             1.00   ---                                                   
  1995‐1997                                               177            155             0.91   \[0.73, 1.14\]   .412                                 
  1998‐2000                                               226            200             0.99   \[0.80, 1.22\]   .907                                 
  2001‐2003                                               374            284             0.87   \[0.71, 1.06\]   .161                                 
  2004‐2006                                               337            196             0.88   \[0.71, 1.09\]   .233                                 
  2007‐2009                                               186            56              0.76   \[0.56, 1.04\]   .085                                 
  ***Oncologic characteristics***                                                                                                                     
  Grade                                                                                                          **\<.001**                           **.032**
  Well‐differentiated                                     44             28              1.00   ---                           1.00   ---              
  Moderately‐differentiated                               354            238             1.23   \[0.83, 1.82\]   .298         1.29   \[0.87, 1.83\]   
  Poorly or undifferentiated                              867            644             1.57   \[1.08, 2.29\]   .020         1.48   \[1.01, 2.11\]   
  NOS                                                     207            146             1.26   \[0.84, 1.89\]   .260         1.22   \[0.81, 1.75\]   
  Receptor status                                                                                                **\<.001**                           **\<.001**
  Any positive receptor                                   772            520             1.00   ---                           1.00   ---              
  Negative receptors (ER‐/PR‐)                            457            334             1.52   \[1.33, 1.75\]   \<0.001      1.70   \[1.47, 1.95\]   
  Unknown                                                 243            202             1.40   \[1.19, 1.64\]   \<0.001      1.37   \[1.16, 1.59\]   
  Lymph nodes examined                                                                                           **\<.001**                           **\<.001**
  None                                                    298            241             1.21   \[1.03, 1.42\]   0.020        1.00   ---              
  1‐11                                                    552            384             1.00   ---                           0.49   \[0.38, 0.65\]   
  \>12                                                    545            366             0.93   \[0.81‐1.08\]    0.347        0.36   \[0.27, 0.48\]   
  Unknown                                                 77             65              1.61   \[1.24‐2.10\]    \<0.001      0.39   \[0.21, 0.73\]   
  Lymph nodes positive                                                                                           **\<.001**                           **\<.001**
  No lymph nodes examined                                 146            70              1.00   ---                           1.00   ---              
  0                                                       274            169             1.38   \[1.04, 1.83\]                1.49   \[1.12, 1.98\]   
  1‐3                                                     355            252             1.93   \[1.48, 2.51\]                3.31   \[2.49, 4.41\]   
  4‐9                                                     337            268             2.60   \[2.00, 3.39\]                2.10   \[1.60, 2.75\]   
  \>10                                                    62             56              3.34   \[2.34, 4.75\]                4.23   \[2.22, 8.09\]   
  **Treatment characteristics**                                                                                                                       
  Radiation therapy (XRT)                                                                                                                             
  XRT                                                     893            604             0.74   \[0.65, 0.84\]   **\<.001**                           
  No XRT                                                  579            452             1.00   ---                                                   
  Pre‐Op XRT                                                                                                                                          
  Yes                                                     63             53              1.09   \[0.82, 1.43\]   .559                                 
  No                                                      1409           1003            1.00   ---                                                   
  Post‐Op XRT                                                                                                                                         
  Yes                                                     839            559             0.74   \[0.66, 0.84\]   **\<.001**   0.83   \[0.72, 0.95\]   .007
  No                                                      633            497             1.00   ---                           1.00   ---              
  Chemotherapy status                                                                                                                                 
  Yes                                                     957            643             0.73   \[0.65, 0.83\]   **\<.001**                           
  No                                                      515            413             1.00   ---                                                   
  Pre‐Op Chemotherapy                                                                                                                                 
  Yes                                                     696            462             0.81   \[0.72, 0.92\]   **.001**     1.10   \[0.95, 1.27\]   .220
  No                                                      776            594             1.00   ---                           1.00   ---              
  Post‐Op Chemotherapy                                                                                                                                
  Yes                                                     723            485             0.77   \[0.68, 0.87\]   **\<.001**   0.86   \[0.75, 0.99\]   .034
  No                                                      749            571             1.00   ---                           1.00   ---              

*P*‐value in bold denote Wald joint Chi‐square tests for overall significance of the predictor in the model.

*P*‐value not in bold are for pairwise comparisons with the referent.

Region groupings are as follows: Northeast (Connecticut and New Jersey); South (Atlanta, rural Georgia, Kentucky, and Louisiana); Midwest (Detroit and Iowa); West (Hawaii, New Mexico, Seattle, Utah and California).
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With adjustment for covariates, IBR was no longer associated with lower OM (HR = 0.82, CI 0.55‐1.21; *P* = .319) (Table [4](#cam41546-tbl-0004){ref-type="table"}). Independent predictors of OM were: age of diagnosis (*P* \< .0001), CCI (*P* \< .0001), histologic grade (*P* = .0318), HR status (*P* \< .0001), number of LN examined (*P* \< .0001), number of positive LN (*P* \< .0001), adjuvant radiation therapy (*P* = .0066), and adjuvant chemotherapy (*P* = .0343). Similar to BCSM, observations of aggressive histologic grade and HR status were associated with increased risk of OM. Similar relationships were demonstrated between BCSM and both examined and positive LN.

To examine the association of chemotherapy and radiation therapy with BCSM over time, we stratified the cohort into 4 time periods, and looked at differences in BCSM by treatment within each period. The cumulative incidence of BCSM was significantly greater in chemotherapy patients in the first period (1991‐1995, Gray's test *P* = .0008). Each successive period (1996‐2000; 2001‐2004; 2005‐2009) did not demonstrate a difference by chemotherapy or radiation therapy status (each Gray's test *P* \> .05). When examined in the multivariable modeling, the interaction between time period and additional treatment was not statistically significant.

3.4. Cumulative incidence of breast cancer‐specific and overall mortality associated with immediate breast reconstruction {#cam41546-sec-0007}
-------------------------------------------------------------------------------------------------------------------------

There was no difference in BCSM or adjusted BCSM (sHR 1.04; CI 0.71‐1.54; *P* = .83 and sHR 1.13; CI 0.84‐1.93; *P* = .582, respectively) when comparing reconstruction status (Figure [1](#cam41546-fig-0001){ref-type="fig"}A,C). Immediate breast reconstruction was associated with a lower OM risk compared to patients not having IBR (hazard ratio \[HR\] 0.63; CI 0.42‐0.92; *P* = .018), but this difference was no longer significant after adjusting for age, comorbidities, and other covariates (Figure [1](#cam41546-fig-0001){ref-type="fig"}B,D). Reconstruction status did not affect BCSM or OM regardless of HR status or histologic grade (data not shown).

![A‐D, Cumulative incidence of unadjusted and adjusted breast cancer‐specific mortality (BCSM) and overall mortality (OM) associated with immediate reconstruction status accounting for competing risk of other causes of death (A, Unadjusted BCSM; B, Unadjusted OM; C, Adjusted BCSM; D, Adjusted OM)](CAM4-7-2887-g001){#cam41546-fig-0001}

4. DISCUSSION {#cam41546-sec-0008}
=============

Historically, the 5‐year overall survival for IBC following mastectomy alone was 2%‐4%.[25](#cam41546-bib-0025){ref-type="ref"} Strategies for IBC treatment transitioned to radiation therapy alone or combined with surgery, but did not confer survival improvement. Recently, advances in multimodal therapy have improved the 5‐year overall survival rate to 34%‐47%.[6](#cam41546-bib-0006){ref-type="ref"} Multimodal therapy consists of neoadjuvant chemotherapy, modified radical mastectomy, and postmastectomy radiotherapy.[6](#cam41546-bib-0006){ref-type="ref"}, [7](#cam41546-bib-0007){ref-type="ref"} Given the prognostic improvement, IBC that was once a relative contraindication to reconstruction has been given new reconsideration.

A few single‐institution studies have investigated whether breast reconstruction affects oncologic and survival outcomes among IBC patients.[3](#cam41546-bib-0003){ref-type="ref"}, [16](#cam41546-bib-0016){ref-type="ref"}, [17](#cam41546-bib-0017){ref-type="ref"} Chin et al[3](#cam41546-bib-0003){ref-type="ref"} reported no difference in disease‐free or overall survival when comparing 22 IBC patients to nonreconstructed historical controls. The median disease‐free and overall survival rates were 19 and 22 months, respectively. No differences in oncologic outcomes were observed between 14 IBR patients and the remaining delayed reconstruction patients. Chang et al[16](#cam41546-bib-0016){ref-type="ref"} performed a 12‐year retrospective review of 830 IBC patients and demonstrated improved overall survival and similar complication rates when comparing 59 free autologous reconstruction IBC patients to their nonreconstructed counterparts. Of note, only 7 patients underwent IBR with free tissue. When examining a large, multicenter cohort of postmastectomy patients undergoing autologous breast reconstruction, Song and colleague demonstrated that women over age 65 years, accounting for 3% of the entire cohort, tolerated reconstruction with high satisfaction, and had no significant differences in postoperative complications as compared to younger patients.[26](#cam41546-bib-0026){ref-type="ref"} Moreover, whether breast reconstruction was implant‐based or autologous tissue, advanced age did worsen recovery or long‐term morbidity.[27](#cam41546-bib-0027){ref-type="ref"} Recently, Simpson et al[17](#cam41546-bib-0017){ref-type="ref"} identified 16 IBC women who received IBR, where the majority were tissue expander‐based procedures. Similar to their 6% implant‐related complication rate,[17](#cam41546-bib-0017){ref-type="ref"} we report a 7% complication rate in our cohort of IBC patients. While reconstruction‐associated complications did occur, IBR was not associated with elevated recurrence or lowered survival. These studies suggest that both delayed and immediate breast reconstruction are oncologically safe, well tolerated, and do not impact survival.

To our knowledge, the only 2 studies that evaluate survival in any meaningful manner, which are good studies, but do markedly differ from ours. The first paper by Chang and colleagues[16](#cam41546-bib-0016){ref-type="ref"} is a single‐institution retrospective analysis of 59 IBC patients who primarily underwent delayed autologous reconstruction. In this study, there was no control group comparison for mortality. The second study by Simpson and colleagues[17](#cam41546-bib-0017){ref-type="ref"} is a single‐institution review of breast reconstruction in IBC patients with a control group that demonstrated that immediate breast reconstruction was not associated with decreased survival. However, this study's conclusion was based on the limited IBC cohort of 16 patients who underwent immediate reconstruction.

We performed a population‐based study using the SEER‐Medicare dataset to evaluate mortality in a nationally representative cohort of IBC patients, and beyond recent studies, we confirmed an association between IBR status and IBC outcomes.[28](#cam41546-bib-0028){ref-type="ref"}, [29](#cam41546-bib-0029){ref-type="ref"}, [30](#cam41546-bib-0030){ref-type="ref"} Agarwal et al demonstrated in their SEER database study of all breast cancer postmastectomy patients that reconstructed women had a lower hazard of OM when compared to nonreconstructed women.[29](#cam41546-bib-0029){ref-type="ref"} In a follow‐up study, they demonstrated greater breast cancer‐specific survival in patients that underwent reconstruction, although this may have been due to selection bias.[30](#cam41546-bib-0030){ref-type="ref"} These studies validate our unadjusted finding that OM was improved follow mastectomy and IBR. Although we also demonstrated that IBR did not confer an OM benefit after adjusting for potential confounders in the 44 postmastectomy IBC patients when compared to the 1428 nonreconstructed IBC women, we found that IBC patients who have IBR after mastectomy have similar BCSM in comparison with IBC patients who do not undergo reconstruction. No difference in mortality was present after adjustment. To our knowledge, this represents the largest study of mortality in IBR IBC patients.

Our evaluation demonstrated that more recent IBC diagnosis was associated with a progressive reduction in hazard of death. Improvement in BCSM is multifactorial. Over recent decades, targeted and less toxic chemotherapeutic protocols have been developed.[31](#cam41546-bib-0031){ref-type="ref"} The most recent 2016 NCCN guideline for IBC recommends preoperative systemic chemotherapy using anthracycline‐ and taxane‐based therapy with the addition of HER2‐targeted therapy in tumors with HER‐2/neu overexpression.[9](#cam41546-bib-0009){ref-type="ref"} Additional improvements appear to be due to advances in diagnostic technology that detect IBC earlier, which translate to earlier treatment, and adoption of multimodality treatment to improve oncologic outcomes for IBC patients.[5](#cam41546-bib-0005){ref-type="ref"}, [6](#cam41546-bib-0006){ref-type="ref"}, [7](#cam41546-bib-0007){ref-type="ref"}, [8](#cam41546-bib-0008){ref-type="ref"}

While our review of the SEER‐Medicare dataset was not designed to evaluate the IBR itself or most optimal method of reconstruction in IBC patients, we did find that performance of IBR overall does not present the oncologic concerns previously theorized. Additionally, this analysis confirmed prior findings[29](#cam41546-bib-0029){ref-type="ref"}, [30](#cam41546-bib-0030){ref-type="ref"} that tumor characteristics, such as histological grade, positive receptor status, and lymph node involvement, are independent predictors of adjusted OM and BCSM in IBC patients undergoing IBR. Women with IBC were more likely to undergo mastectomy and IBR if they were younger, married, healthier, and had greater median income. Yet, the single predictor of undergoing IBR was median income. This may suggest that wealthier areas have improved access to care and have the opportunity to benefit from IBR to enhance body image, self‐esteem, and quality of life without compromising oncologic and survival outcomes or increasing complications.[11](#cam41546-bib-0011){ref-type="ref"}, [12](#cam41546-bib-0012){ref-type="ref"}, [16](#cam41546-bib-0016){ref-type="ref"}, [17](#cam41546-bib-0017){ref-type="ref"}

The unique nature of this study is its national representation of patient demographics and tumor characteristics allowing greater generalizability of our results nationally via the Medicare population. While this cohort is 65 and over, there is little reason why our results should be inapplicable to a younger population, but as recurrence rates can be slightly higher in a younger cohort, additional study in this group is indicated. Epidemiologic studies report that IBC accounts for 0.5%‐2% of invasive breast cancers and is diagnosed at an earlier age (mean of 59 years vs 62 years).[2](#cam41546-bib-0002){ref-type="ref"}, [4](#cam41546-bib-0004){ref-type="ref"} We identified approximately 0.3% (n = 1472) of nonmetastatic IBC patients among the overall breast cancer SEER‐Medicare cohort (n = 552 936). Our IBC study cohort had a greater mean age at diagnosis of 75.5 years compared to the overall SEER invasive breast cancer cohort (mean age 59 years).[4](#cam41546-bib-0004){ref-type="ref"} In comparison with the overall age of invasive breast cancer SEER patients, we observed a smaller, older cohort of IBC patients from examining only the SEER‐Medicaid linked database. While our conclusions are limited to an older IBC population, we anticipate that an inclusive cohort of IBC patients will demonstrate a survival benefit with IBR.

Elderly postmastectomy breast reconstruction patients are underrepresented,[27](#cam41546-bib-0027){ref-type="ref"} and even more so in the subgroup of IBC patients. This is evident in our small sample size, and this is likely due to the fact that IBR is presently considered contraindicated for IBC patients. But as the United States population overall and IBC patients specifically are showing an increasing longevity, denial of IBR in the IBC setting for historic reasons may no longer be justified and should remain an option. We believe our study is a good starting point for further consideration and analysis, and our data are the best evidence to date that IBR has little impact on mortality.

Although the present study was not designed to analyze the perioperative complications associated with and without IBR in the elderly cohort, reconstruction remains safe and is performed frequently in those over 65. While postmastectomy radiation is known to increase the risk of postmastectomy IBR complications,[32](#cam41546-bib-0032){ref-type="ref"} our analysis of SEER‐Medicare data results suggest that age, Charlson comorbidity scores, and radiation therapy do not increase risk of BCSM. We found that fewer older IBC patients in the SEER‐Medicare dataset (Table [1](#cam41546-tbl-0001){ref-type="table"}) received radiation therapy than expected (40%). To determine whether this was unique to the older IBC cohort, we re‐analyzed the SEER variable for radiation use (as vs Medicare claims codes) for the overall breast cancer population. We found that indeed a large proportion did not receive radiation (47%), and this finding was similar to our results. Similar findings were demonstrated after review of lymph node examination. Although these numbers seem low, the older IBC population is a group in whom selective omission of various treatments may occur more frequently. Our analysis attempts to compensate for such findings, by adjusting for adjuvant therapy usage or omission, so these numbers should have minimal impact on our analysis. Moreover, we believe that such numbers, if they had an effect, would skew the data away from our conclusion of similarity between groups. Yet we still found no difference, further strengthening our argument about safety. Therefore, our data offer guidance to counseling older IBC patients regarding the impact of surgical treatment on postoperative outcomes and BCSM.

Although this dataset does not include every possible comorbidity, we utilized Charlson Comorbidity Index to adjust for health issues that may affect mortality. Moreover, while our focus is on the issue of survival and outcomes with or without reconstruction, we recognize that components of treatment may impact outcomes related to reconstruction (eg, radiation‐related complications of implant breast reconstruction). Now that we have demonstrated that cancer outcomes are not compromised by the reconstruction, the secondary consideration of how to avoid or minimize such complications in the setting of radiotherapy should be evaluated in additional studies.

Finally, while we can see no reason why these results would markedly differ from a similar study in a younger cohort, confirmation in those under 65 would be desirable. Although younger patients have a higher recurrence risk, the added risk is present whether patients have mastectomy or breast conservation. We therefore do not think that the performance of breast reconstruction in younger women should change outcomes or show results any differently than it does here. Such a marked treatment difference by age would be a highly unique finding. Despite these limitations, our current analysis of a national cohort of IBC patients represents an important step in examining the interaction of IBR and BCSM.

As women with IBC now undergo multimodal treatment that confers a disease‐specific mortality that is markedly improved compared with outcomes that occurred when IBR was first considered contraindicated, these results should provide reassurance to patients and multidisciplinary teams that the addition of IBR does not have a negative impact on BCSM. Ultimately just because we can do something does not mean we should*,* but our evaluation suggests that IBR is safe, and should not be considered a contraindication in carefully selected IBC patients.

CONFLICT OF INTEREST {#cam41546-sec-0010}
====================

There are no conflicts of interest.

Supporting information
======================

###### 

 

###### 

Click here for additional data file.

This work was supported by United States Public Health Services grant P30 CA006927 for analysis of the data via support of our biostatistics facility, by an internal American Cancer Society grant \#IRG‐92‐027‐17 that supported preliminary analysis of data, and by generous private donor support, for analysis and interpretation of the data. This study used the linked SEER‐Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the National Cancer Institute; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER‐Medicare database. The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement \# U58DP003862‐01 awarded to the California Department of Public Health. The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of California Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred. The authors acknowledge the efforts of the National Cancer Institute; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER‐Medicare database.
